Film 83013: Strategies for Successful Intracapsular Administration of Dexamethasone Intraocular Suspension 9% | ASCRS
Video
Film 83013: Strategies for Successful Intracapsular Administration of Dexamethasone Intraocular Suspension 9%
April 2022
Meeting: 2022 ASCRS Annual Meeting
Presenting Author: Lisa Nijm, MD, JD , ABO
Category: Cataract/Implant Surgery
This content is only available to 2022 ASCRS Annual Meeting phyisican registrants

To log in, click the teal "Login" button in the upper right-hand corner of this page. If you are logged in but still do not have access, please check your 2022 Annual Meeting registration.

Since the bioerodible, sustained-release dexamethasone intraocular suspension 9% was approved for postoperative inflammation, surgeons have been working to optimize its administration. Most recently, we have found success injecting the drug directly into the capsular bag, adjacent to the intraocular lens implant. This video will demonstrate strategies for success with intracapsular delivery.

We use cookies to measure site performance and improve your experience. By continuing to use this site, you agree to our Privacy Policy and Legal Notice.